Figure 3. Increased glutamate release elevates ISF Aβ levels which requires endocytosis.
(A) ISF A levels in Tg2576 mice treated with dynamin-DN or vehicle followed by LY341495, an mGluR2/3 antagonist that increases pre-synaptic glutamate release. (B) LY341495 increased ISF A levels by 122.2 ± 8.4% during hours 6-8 of treatment (p<0.05, n = 4). The increase in A levels was prevented by pretreatment with dynamin-DN (n = 4). Data presented as mean ± SEM. * represents p<0.05.